Veru is a Miami-based drug developer working on enobosarm for obesity and sabizabulin for inflammatory heart disease. It last closed at $1.94 on Nov 20, down 8.06% on the day. The next earnings report for VERU is expected around Wed, Dec 16, 2026. For the quarter ended Jun 2026, VERU reported EPS of -$0.30. Over its last 8 reports the stock moved an average of 6.8% the session after earnings. Over the last 12 months VERU insiders bought $5K of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is VERU in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VERU.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on VERUStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
VERU · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold
The stock is 11% below its 20 day and 19% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the 52 week low at $1.93, and the nearest resistance the Pivot at $2.01.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 7.2%/day
Key levels
$7.3352 week high+277.8%
$2.46200 day average+26.8%
$2.43100 day average+25.3%
$2.3150 day average+19.1%
$2.21Swing high (Nov 10)+13.9%
$2.1620 day average+11.3%
$2.10Pivot R1+8.2%
$2.01Pivot+3.6%
$1.94Last close
$1.9352 week low−0.5%
$1.86Pivot S1−4.1%
Indicators
RSI (14)
37.23
Weak, oversold below 30
Neutral
MACD
-0.07
Below its signal line
Bearish
Stochastic
39.5
Middle of its range
Neutral
ADX (14)
12.5
No clear trend
Williams %R
-97.6
Oversold below −80, overbought above −20
Oversold
CCI (20)
-181.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−8.5%
Change over 10 sessions
Bearish
ATR (14)
$0.14
Typical daily range, 7.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityLow, 17.9%/day
Key levels
$7.3352 week high+277.8%
$2.46200 day average+26.8%
$2.43100 day average+25.3%
$2.3150 day average+19.1%
$2.21Swing high (Nov 10)+13.9%
$2.1620 day average+11.3%
$2.10Pivot R1+8.2%
$2.01Pivot+3.6%
$1.94Last close
$1.9352 week low−0.5%
$1.86Pivot S1−4.1%
Indicators
RSI (14)
34.70
Weak, oversold below 30
Neutral
MACD
-0.15
Below its signal line
Bearish
Stochastic
5.5
Near the bottom of its range
Oversold
ADX (14)
34.6
Trending up
Williams %R
-98.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-129.0
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.5%
Change over 10 sessions
Bearish
ATR (14)
$0.35
Typical daily range, 17.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VERU
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how VERU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow VERU usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for VERUHow many large options trades hit VERU, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in VERU in the last 90 days.
From SEC Form 4 filings by VERU's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERU is in one of them and how their past VERU trades turned out.
Veru is a drug development company based in Miami, Florida. Its lead candidate, enobosarm, is an oral medicine designed for patients with obesity who take GLP-1 drugs, with the aim of helping them keep muscle while losing fat. Its second candidate, sabizabulin, is being studied as a treatment for inflammation in atherosclerotic cardiovascular disease, a condition in which fatty deposits build up in the arteries. The company's candidates are aimed at patients with these conditions and the doctors who treat them.